15-min delayed · Sep 4, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 16 firms covering Moderna Inc, 3 rate it Buy or better, 10 sit at Hold, and 3 rate it Sell or worse, a hold consensus. The target range is very wide, $18.00 to $180.00 (about 10.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $81.46 sits 44% below the current $145.54. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 1 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.74 next quarter toward $-4.93 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS16 ratings
Hold
Strong Buy00%
Buy319%
Hold1063%
Sell319%
Strong Sell00%
Based on 16 analysts giving stock ratings to Moderna Inc.
As of Sep, 3 of 16 firms rate MRNA a Buy (10 Hold, 3 Sell), the standing distribution of every covering firm's most recent active call.
MRNA EPS & revenue forecast
EPS · NEXT QUARTER
$-1.74
Range $-2.09 – $-0.63 · 14 analysts · -17% YoY
Next period, 14 analysts expect Moderna Inc to earn $-1.74 a share (range $-2.09 – $-0.63), versus $-2.11 a year earlier. Full-year consensus is $-8.41, growing to $-4.93 the year after.
REVENUE · NEXT QUARTER
$667.8M
Range $379.0M – $734.0M · 14 analysts · -2% YoY
Revenue is expected to reach $667.8M (range $379.0M – $734.0M), -1.5% year-over-year. Full-year consensus is $2.1B, rising to $2.4B next year.
Top analysts covering Moderna Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MRNA.
#1
Luca Issi
RBC Capital · Rank #1
Hold
$130.00-10.7% to target
Overall win rate
55%
+ Follow
#2
Jessica Fye
JP Morgan · Rank #71
Sell
$77.00-47.1% to target
Overall win rate
53%
+ Follow
#3
Joseph Stringer
Needham · Rank #195
Hold
No targeton MRNA
Overall win rate
36%
+ Follow
#4
Matthew Harrison
Morgan Stanley · Rank #300
Hold
$39.00-73.2% to target
Overall win rate
45%
+ Follow
#5
Edward Tenthoff
Piper Sandler · Rank #337
Buy
$77.00-47.1% to target
Overall win rate
29%
+ Follow
MRNA stock forecast FAQ
What is MRNA's average 12-month price target?+
The 13 analysts with a live target average $81.46 for Moderna Inc over the next 12 months, ranging from a $180.00 high to a $18.00 low.
Is MRNA stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 16 analyst ratings, 3 are Buy or Strong Buy, 10 are Hold, and 3 are Sell or Strong Sell.
What are the highest and lowest price targets for MRNA?+
The Street-high target is $180.00 (Argus Research), and the Street-low is $18.00 (Leerink Partners). The average of all 13 active targets is $81.46.
How many Wall Street analysts cover MRNA?+
16 analysts have an active rating on Moderna Inc, and 13 firms carry a live 12-month price target.
Who is the most accurate analyst covering MRNA?+
Among analysts who currently cover MRNA, Luca Issi of RBC Capital has the strongest overall Quantellect track record (Rank #1). Their current call is Hold with a $130.00 target.
What is Moderna Inc's projected EPS for next quarter?+
The consensus estimate is $-1.74 per share (range $-2.09 – $-0.63) across 14 analysts. Full-year EPS is projected at $-8.41, rising to $-4.93 the following year.
How much revenue is Moderna Inc expected to report next quarter?+
Consensus revenue is $667.8M (range $379.0M – $734.0M). Full-year revenue is projected at $2.1B, growing to $2.4B next year.
Have analysts been upgrading or downgrading MRNA lately?+
As of Sep, 3 of 16 firms rate MRNA a Buy (10 Hold, 3 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MRNA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
